Patients or their carers were interviewed about resource utilization and absenteeism from work in the past year. Direct medical costs included outpatient visit, hospitalization, ambulatory, drug, diagnostic tests, and physiotherapy costs. Indirect costs were estimated using a human capital approach. All costs referred to 2011. RESULTS: Among 156 patients with AFrelated stroke, 59.35% were male and the mean age was 67.9±30.2 years. 98.0% patients have at least one kind of health insurance. From the societal perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 25538 (median: CNY13342, IQR: CNY7662-CNY 38714), with direct costs accounting for 94.2% and indirect costs for 5.8% of the total. And for the direct costs, the informal care costs were CNY9162. The drug costs were CNY6293. Based on the prevalence of AF and AF-related stroke in China from literatures, there was about 0.968 million patients of AF-related stroke. Costs for the nation are estimated at CNY24.7 billion per year. CONCLUSIONS: The economic burden of AF-related stroke in China is considerable. The primary burden on patients was due to informal care and drugs.
OBJECTIVES: Though the burden of illness (BOI) in Atrial Fibrillation (AF) is unknown in China, reports from developed countries demonstrated that BOI in AF is significant. This study is to analyze the economic burden of AF in China. METHODS: A systematic review of studies on AF was conducted in both English and Chinese databases from 2000 to 2012. Epidemiologic and economic data were abstracted to analyze the two key measures of BOI in AF: the Disability Adjusted life Year (DALY) loss in AF and the BOI in stroke attributable to AF. RESULTS: The BOI in stroke attributable to AF was RMB 4.9 billion annually of which 89% was consumed by the patients above 60. The DALYs loss in AF amounts to 4,599,687 in total for the population above 30, which outstrips the DALYs loss in hypertensive heart disease (3, 348, 925) and is very close to the DALYs loss in diabetic mellitus (4, 769, 127) . The patients with the age below 60 contribute to 31% of the total DALYs loss. The DALYs loss in male is more than the loss in female (55% vs. 45%). The average DALYs loss increases with age in the whole lifetime. Stroke was confirmed as the leading contributor to the DALYs loss among AF patients, accounting for 44.21% followed by heart failure (38.14%) and myocardial infarctions (17.65%). CONCLUSIONS: The BOI in AF in China is considerably significant. Stroke is the driver of BOI in AF in China. The average DALYs loss of AF attributable to stroke is higher than the average DALYs loss of nonfatal stroke in the US (60-69 years old). As the treatment rate of AF is fairly low with little compliance to clinical guidelines, it becomes critical to increase the awareness of AF and its appropriate management to restore the sinus rhythm and reduce consequent stroke.
PCV60 THE COST TO US HOSPITALS FOR HEART FAILURE (HF) INPATIENT ADMISSIONS ACROSS DRGS: A RETROSPECTIVE MULTI-CENTER STUDY
Rizzo JA 1 , Gunnarsson C 2 , Burton ML 3 , Mollenkopf SA 3 , Bril SL 4 , Tsintzos S 3 1 Stony Brook University, Port Jefferson, NY, USA, 2 S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3 Medtronic, Inc., Mounds View, MN, USA, 4 Medtronic, Inc, Mounds View, MN, USA OBJECTIVES: Heart Failure (HF) represents the most costly condition for the Medicare population and one of the most common reasons for admission to US Hospitals. This study sought to quantify the actual hospital costs for these admissions looking at different diagnoses and varying severities. METHODS: Using the Premier hospital database, admissions from year 2010 were included if they met the following criteria: (a) one or more inpatient admission(s) with an International Classification of Diseases, Ninth Revision (ICD-9) primary diagnosis code of HF (both chronic and acute HF) and (b) Diagnosis-Related Group (DRG) Codes 291-Complications and Comorbidities, 292-Comorbidities or 293-Without any Complications and Comorbidities. Patients with an implantable cardiac device (e.g. ICD, CRT-D) were excluded. HF admissions were analyzed by DRG. Summary statistics were generated for the cost to the hospital overall and for each DRG code. RESULTS: A total of 592,279 inpatient admissions with a HF Diagnosis code were initially identified; 483,297 were excluded due to evidence of a device and/or a lack of HF-related DRG, leaving 108,982 admissions. Of the admissions that met the criteria, 44% were classified as DRG 291, 36% DRG 292, and 20% DRG 293. Mean costs were $8184 (SD $8,015; median $6140; first quartile (Q1) $3989, third quartile (Q3) $9691). Total costs of an admission were 51% fixed and 49% variable. Mean Length-of-Stay for admissions was 4.92 days (SD 4.74; median 4.00; Q1 2.00, Q3 6.00). Looking at DRGs separately, DRG 291 had the highest mean cost $10,558 (SD $10,033.6), followed by 292 $7,017 (SD $5,728) and 293 $5,067 (SD $4,091). CONCLUSIONS: The cost of a HF hospitalization typically exceeded the average reimbursement provided by Medicare which in 2010 was $8245, $5947, and $3917 for DRGs 291, 292, and 293, respectively. Heart Failure is a highly prevalent and costly condition that imposes a significant burden on US hospitals.
OBJECTIVES: Acute Coronary Syndromes (ACS) often occurs in working-age individuals. Limited data exist on the burden of ACS on employees. We attempted to determine the total burden of illness, including the direct and indirect costs associated with ACS for employees and their dependents. METHODS: Medical and pharmacy claims (IMS LifeLink data) along with short term disability (STD) and long term disability (LTD) claims (Integrated Benefits Institute's Health and Productivity Benchmarking Database) from 2007-2010 were analyzed. Indirect cost analyses consisted of work days lost and wage replacement costs for the employers. Direct costs consisted of total all-cause and ACS related health costs for those newly diagnosed with ACS in the 12 month period following diagnosis. To make direct and indirect costs comparable between the two databases, all health care cost estimates were weighted by analytic weights derived from age and gender distributions of both datasets. RESULTS: A total of 37,340 employees had STD or LTD claims for ACS. The majority (77.4%) was male; 94% were less than 65 years of age. Employees with ACS had on average 60.2±SE:0.29 STD and 397.9±SE:8.09 LTD days per disability incident. For employers, the estimated per claim productivity loss for STD and LTD were $7,943±SE:39.7 and $52,473±SE:1,114, respectively. Total annual ACS health care costs were $8,170±SE:106. Hospitalizations accounted for 75% of total annual ACS health costs. Out of the total number of employees (n=29,100), 36% had one or more hospitalizations for ACS. When examining this specific cohort of patients hospitalized for ACS, the mean total annual ACS health care costs per patient more than doubled ($18,899±SE: 253) CONCLUSIONS: These data demonstrate that ACS imposes a substantial economic burden on employees. Long term productivity losses and disability costs are significant for employers. ACS related hospitalizations represent a large portion of total medical costs. OBJECTIVES: Identify the direct costs in angioplasty patients in private hospitals in Brazil. METHODS: It was selected patients from 3 (three) Brazilian states in the same operator who underwent angioplasty at private hospitals present in Orizon database. Parallely was followed the consumption of these medications during the same period by PBM (Pharmaceutical Benefit Management). RESULTS: A total of 196 patients were identified in a predominantly male population (76%) and above 59 years of age (65%) who underwent angioplasty and subsequently consumed drugs via PBM. We found that the average expenditure per patient with angioplasty with or without stenting in private hospitals corresponds to 5579.07 USD, while spending only with prosthesis corresponded to 13% of the drive. CONCLUSIONS: The treatment of coronary stenoses does not account only V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) A 1 -A 2 9 8 A283 surgical procedures, but also the administration of medicines to control lipids, blood pressure, antidepressants and even hypoglycemia, and even then those expenditures does not consider the indirect expenses such as transportation and escort the patient to the hospital and absence from work. 
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COST OF ANGIOPLASTY IN BRAZILIAN PRIVATE HOSPITALS
PCV63 ESTIMATING THE COSTS OF CARDIAC REHABILITATION PROGRAMS IN HEART FAILURE (HF) IN COLOMBIA: CONSTRUCTION BASED ON EXPERT CONSENSUS
OBJECTIVES:
To determine the components and the costs of an exercised-based rehabilitation program for patients with chronic systolic HF, from the point of view of the provider of the service. METHODS: Systematic review of the literature and expert consensus. Identification of components of HF rehabilitation programs, based on the literature, and Delphi rounds of experts for consensus. Only variable costs associated with the components of the program were estimated, based on the Colombian 256 agreement of 2001 (the Colombian norm that set the tariff for reimbursement for health care services) plus 23%, 30%, or 48%, to approximate the range of costs in current (2012) health care package negotiations in Colombia between providers and payers. For 2012, US$1=COL$1,783. RESULTS: Based on expert consensus of cardiologists and physical therapists, 18 components of the rehabilitation program were identified. After the second round, over 80% agreement was obtained for the remaining three components, and an additional component was identified. After the third round, consensus was obtained for a program of 36 rehabilitation sessions and 19 components. With the base-case scenario of agreement 256 plus 30%, the cost per session of the program was inversely proportional to the number of patients in each session: COL $96,903 for one patient, and COL $11,623 for 15 patients. For a program with 10 patients per session, the costs of a program may range from COL$ 471,130 to COL $656,554, depending on the agreement type. CONCLUSIONS: Agreement is critical to unify criteria on the components of a rehabilitation program that is both effective and safe for patients with HF. From the point of view of the provider, variable costs associated with implementation are sensitive to the number of patients per session. This study should set the basis for the estimation of the cost-effectiveness of rehabilitation programs in heart failure.
PCV64 ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN PREVENTING HOSPITALIZATION IN CARDIOVASCULAR DISEASE PATIENTS
Peasah SK 1 , Meltzer M 2 1 Centers for Disease and Prevention, Atlanta, GA, USA, 2 Centers for Disease Control and Prevention, Atlanta, GA, USA OBJECTIVES: Although the Advisory Committee for Immunization Practices (ACIP) and other organizations recommend annual influenza vaccination for cardiovascular disease patients (CVD), the vaccination rate is low in this risk group. Economic assessment of vaccination will aid public officials plan campaigns to increase coverage. METHODS: We estimated using a Monte Carlo (probabilistic) spreadsheet-based decision tree, the cost-effectiveness of vaccination to prevent hospitalization and death in all 27.1 million CVD patients in the US. We then estimated the benefit-cost ratios (BCR) associated with hospitalization and death averted by increasing coverage rates by 10% in all adult CVD patients from the current rates of 45% and 65% (for ages <65 years and ≥65 years, respectively). Finally, we estimated the BCR associated with reaching the healthy people 2020 goal of vaccinating 90% of person's ≥65 years and 80% of adults' <65 years. We obtained treatment cost data from Marketscan database (2005) (2006) (2007) (2008) (2009) (2010) and epidemiological data from the literature. We performed the analysis from the health care perspective including only cost associated with hospitalization and vaccination and reporting median cost values. RESULTS: Vaccination of all 27.1 million CVD patients' would result in the following: 20,738 (S.D 48,387)) quality-adjusted life years (QALY) saved, $10,107 (95% CI: costsavings (CS) to $70,554) / QALY saved, $31,563 (CI: CS to $151,900)/ hospitalization averted, and $76,588 (CI: CS to $534,658)/ premature death averted. The base case BCR is 0.52. A 10% increase in vaccination rate costing $41.2million (S.D $7.2 million) would result in hospitalization-related savings of $28 million (S.D. $165 million) (BCR=0.68). Achieving healthy 2020 goal would cost $257 million (S.D. $45 million) and result in $ 216 million (S.D. $1.4 billion) hospitalization savings (BCR=0.84). CONCLUSIONS: Increasing vaccination coverage rate among CVD patients will avert hospitalization and most likely deaths, but with variability in economic impact.
PCV65 QUANTITATIVE RISK-BENEFIT ANALYSIS OF ORAL PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE DYSFUNCTION TREATMENT
Hsu JC 1 , Tang D 2 1 National Cheng Kung University, Taipei, Taiwan, 2 University of Arizona, Tucson, AZ, USA OBJECTIVES: Erectile dysfunction is a common male sexual disorder worldwide. Three oral medications -sildenafil, vardenafil, and tadalafil -have been used to treat erectile dysfunction. This study aimed to conjointly evaluate the therapeutic risks and benefits of the three medications to assist decision making of prescribing from the perspective of both physicians and patients. METHODS: A decision model was created to compare the risk-benefit of the aforementioned medications. Using published meta-analysis data, we performed a probabilistic Monte Carlo simulation to estimate the joint distribution of each type of adverse event (i.e., risk; categories included: any adverse event, serious cardiovascular (CV) events, headache, flushing, and dyspepsia) and effectiveness (defined as proportion of patients with improved erections). The incremental risk-benefit ratios (ICBRs) were calculated, and the results were illustrated by incremental risk-benefit planes. To account for differential risk preferences across patients, the results were also illustrated using risk-benefit acceptability curves and netbenefit curves. RESULTS: When risk was defined as having any adverse event, serious CV event, or headache, sildenafil was dominated by vardenafil (ICBR= -1.00, -0.20, and -3.20, respectively); tadalafil showed increasing risk and benefit as compared to vardenafil (ICBR=0.83, 0.03, and 0.13, respectively). Tadalafil dominated sildenafil and vardenafil when balancing between the risk of flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients' concern of various categories of adverse events and assuming negligible concern over medical costs, vardenafil or tadalafil may be preferred over sildenafil.
PCV66 ESTIMATING COSTS SAVINGS FROM A CME ACTIVITY TO PREVENT BLEEDING-RELATED COMPLICATIONS AND TRANSFUSION
Ravyn D 1 , Ravyn V 2 , Lowney R 1 , Ferraris VA 3 1 CMEology, West Hartford, CT, USA, 2 University of Colorado, Aurora, CO, USA, 3 University of Kentucky, Lexington, KY, USA OBJECTIVES: In 2011, investments in continuing medical education (CME) exceeded $2 billion. Few studies report the economic impact of CME activities. Greater understanding of the economic value of CME assists stakeholders and health care cost payers in resource allocation. It is not feasible to obtain patientlevel data after each CME activity. We developed a model to estimate the potential health care cost savings associated with CME activity outcomes. METHODS: We evaluated data from a certified CME symposium for surgeons that reviewed the Society for Thoracic Surgeons (STS) blood conservation guidelines. The activity promoted prevention of bleeding-related complications (BRCs). We estimated the potential savings of averted BRCs from the provider perspective predicted by participants' self-reported commitment to change (CTC). Model parameter estimates were from: 1) costs of BRCs in 103,826 cardiac operations; 2) costs of reoperation for bleeding in 133,001 coronary artery bypass graft surgeries; 3) operative volume from the STS workforce report. The base case was 3 in 10 participants preventing one BRC in 2% of operations over 1 year. Probabilistic sensitivity analysis (PSA) using second-order Monte Carlo simulations was used to model parameter uncertainty. Results were standardized to 2012 $US using the medical care component of the Consumer Price Index. RESULTS: 93.8% of participants (n=133) reported CTC, a validated measure of behavior change. For BRCs, the savings for the base case was $1,500,112. PSA estimated the mean savings as $1, 502, 769 (95% CI, $869, 359, 068) . For reoperation for bleeding, the savings for the base case was $2,974,497. PSA estimated the mean savings as $2,959,117 (95% CI, $1,135,992-$5,566,487). CONCLUSIONS: Plausible economic estimates suggest that CMErelated learning favorably impacting clinical practice yields substantial cost savings. Model prediction of averted costs associated with CME allows estimation of the economic impact on surgical outcomes in the absence of patient-level outcomes data related to CME activities. OBJECTIVES: Advanced heart failure (HF) is a leading cause of death in developed countries with a one-year mortality rate estimated at 40% after the first hospitalization. In France, HF affects 150 000 persons with annual costs of up to 1,6 billon euros. Cardiac transplantation is the most effective treatment. However, because of a limited donor organ supply, innovative technics as left ventricular assist devices (LVAD) are developed as bridge to transplantation for over 10 years. The aim of this study is to assess the medical and economic consequences of LVAD in adults with advanced HF in France. METHODS: Between April 2008 and November 2011, 55 patients were included in this study in 14 French hospitals and were followed during one year after implantation. The primary medical outcome was the discharge at home and secondary medical outcome was the final situation of patient. This prospective economic analysis adopted the health care payer's perspective and took into account direct medical and non-medical costs. RESULTS: This intermediate analysis included 21 patients. LVAD used are HeartMate II (n=12), Jarvik 2000 (n=8) and Ventrassist (n=1). On the 21 patients, 15 were discharged at home spending an average of 265 days (8.7 months) at home. During the follow-up period, 4 patients were transplanted, 6 patients died, and 11 were still on device at home. The mean total cost per implanted patient was €161,843 (±36,533). The device and initial hospitalization are the most important costs and represent respectively 58% and 30% of the total cost. One day spent at home costs in average €59 CONCLUSIONS: Continuous-flows LVAD represent a costly strategy in the HF treatment. However, LVAD allow the patient to be discharged at home instead of awaiting heart transplantation at hospital. 
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EVALUATION OF ECONOMIC AND MEDICAL CONSEQUENCES OF THE ROTARY LEFT VENTRICULAR ASSIST DEVICE WITH A DISCHARGE AT HOME IN FRANCE
PCV68 ECONOMIC COMPARISON OF HEMOSTATIC AGENTS IN CARDIAC SURGERY
